Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Theratechnologies (THTX) Reports Publication that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. ("Theratechnologies" or the "Company") (NASDAQ: THTX)..
MONTREAL, Feb. 06, 2024 Theratechnologies Inc. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report.